Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market se

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss

CEO Jonathan Cohen to Detail the Company's Strongest Quarterly Performance Since Commercial Launch o

20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst

Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-O

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetin

20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early marke

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tok

Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement,

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshol

Shares of Super Micro Computer Inc (NASDAQ: SMCI) rose after reporting record backlog of $60B+ in or

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection

Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to I

Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply ag

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Rev

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Rev

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies

20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.28) per share which missed the analyst

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Begin

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an

20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI pow

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repea

Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a B

Healwell AI Inc. (AIDX:CA) Q1 2026 Earnings Call Transcript

Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Fu

Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional

20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.76) per share. This is a 34.48 percent

Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and G

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Det

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Det

Shares of 20/20 Biolabs, Inc. (NASDAQ: AIDX) are trading lower Tuesday after the company announced t

Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed TherapiesExpands On

20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based bl

Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers,